Found: 16
Select item for more details and to access through your institution.
Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study.
- Published in:
- Japanese Journal of Clinical Oncology, 2021, v. 51, n. 8, p. 1261, doi. 10.1093/jjco/hyab072
- By:
- Publication type:
- Article
Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint.
- Published in:
- Nucleic Acids Research, 2017, v. 45, n. 10, p. 5995, doi. 10.1093/nar/gkx325
- By:
- Publication type:
- Article
Casein kinase I δ/ɛ phosphorylates topoisomerase IIα at serine-1106 and modulates DNA cleavage activity.
- Published in:
- Nucleic Acids Research, 2009, v. 37, n. 2, p. 382
- By:
- Publication type:
- Article
A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations.
- Published in:
- International Journal of Clinical Oncology, 2024, v. 29, n. 10, p. 1461, doi. 10.1007/s10147-024-02588-y
- By:
- Publication type:
- Article
Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer.
- Published in:
- International Journal of Clinical Oncology, 2017, v. 22, n. 1, p. 70, doi. 10.1007/s10147-016-1039-0
- By:
- Publication type:
- Article
Erratum to: Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer.
- Published in:
- 2017
- By:
- Publication type:
- Erratum
Analysis of Epidermal Growth Factor Receptor Mutations in Serum Among Japanese Patients Treated With First-Line Erlotinib for Advanced Non-Small-Cell Lung Cancer.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Analysis of Epidermal Growth Factor Receptor Mutations in Serum Among Japanese Patients Treated With First-Line Erlotinib for Advanced Non--Small-Cell Lung Cancer.
- Published in:
- Clinical Lung Cancer, 2016, v. 17, n. 1, p. 24, doi. 10.1016/j.cllc.2015.07.001
- By:
- Publication type:
- Article
Tyrosine 656 in topoisomerase IIβ is important for the catalytic activity of the enzyme: Identification based on artifactual +80-Da modification at this site.
- Published in:
- Proteomics, 2011, v. 11, n. 5, p. 829, doi. 10.1002/pmic.201000194
- By:
- Publication type:
- Article
Extended ICI treatment after first‐line chemoimmunotherapy could predict the clinical benefit of ramucirumab plus docetaxel in advanced non‐small lung cancer: Post hoc analysis from NEJ051 (REACTIVE study).
- Published in:
- Thoracic Cancer, 2024, v. 15, n. 2, p. 163, doi. 10.1111/1759-7714.15173
- By:
- Publication type:
- Article
Safety of anti‐SARS‐CoV‐2 messenger RNA vaccine in lung cancer patients undergoing anticancer chemotherapy: A multicenter, prospective, observational, patient‐reported outcome study.
- Published in:
- Thoracic Cancer, 2023, v. 14, n. 3, p. 231, doi. 10.1111/1759-7714.14737
- By:
- Publication type:
- Article
Short‐term safety of an anti‐severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine for patients with advanced lung cancer treated with anticancer drugs: A multicenter, prospective, observational study.
- Published in:
- Thoracic Cancer, 2022, v. 13, n. 3, p. 453, doi. 10.1111/1759-7714.14281
- By:
- Publication type:
- Article
A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2018, v. 82, n. 6, p. 1031, doi. 10.1007/s00280-018-3694-5
- By:
- Publication type:
- Article
A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Long‐term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study.
- Published in:
- Cancer Science, 2024, v. 115, n. 4, p. 1296, doi. 10.1111/cas.16107
- By:
- Publication type:
- Article
IMpower132: Atezolizumab plus platinum‐based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients.
- Published in:
- Cancer Science, 2021, v. 112, n. 4, p. 1534, doi. 10.1111/cas.14817
- By:
- Publication type:
- Article